<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Urologiia</journal-id><journal-title-group><journal-title xml:lang="en">Urologiia</journal-title><trans-title-group xml:lang="ru"><trans-title>Урология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1728-2985</issn><issn publication-format="electronic">2414-9020</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">636298</article-id><article-id pub-id-type="doi">10.18565/urology.2024.4.81-86</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Comparative study of thulium and holmium laser in non-muscle invasive bladder cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Сравнение тулиевого и гольмиевого лазера при немышечно-инвазивном раке мочевого пузыря</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2767-7153</contrib-id><name-alternatives><name xml:lang="en"><surname>Popov</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Попов</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD, Professor, Chief; Head of the Center of Endourology and New Technologies, Professor at the Department of Urology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, главный врач; руководитель Центра эндоскопической урологии и новых технологий, профессор кафедры урологии</p></bio><email>doc.popov@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9935-0243</contrib-id><name-alternatives><name xml:lang="en"><surname>Guseinov</surname><given-names>R. G.</given-names></name><name xml:lang="ru"><surname>Гусейнов</surname><given-names>Р. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Deputy Director on Scientific Work; Assistant at the Department of Hospital Surgery</p></bio><bio xml:lang="ru"><p>к.м.н., заместитель главного врача по научной деятельности; ассистент кафедры госпитальной хирургии</p></bio><email>rusfa@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pomeshkin</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Помешкин</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Head of the Department of Urology</p></bio><bio xml:lang="ru"><p>к.м.н., заведующий отделением урологии</p></bio><email>pomeshkin@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6664-2861</contrib-id><name-alternatives><name xml:lang="en"><surname>Skryabin</surname><given-names>O. N.</given-names></name><name xml:lang="ru"><surname>Скрябин</surname><given-names>О. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD, Professor, Chief Oncologist, Scientific Chief of the Center of Endourology and New Technologies</p></bio><bio xml:lang="ru"><p>д.м.н., профессор; главный онколог, научный руководитель центра эндоскопической урологии и новых технологий</p></bio><email>skryabin_55@mail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4064-5033</contrib-id><name-alternatives><name xml:lang="en"><surname>Sivak</surname><given-names>K. V.</given-names></name><name xml:lang="ru"><surname>Сивак</surname><given-names>К. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD, Leading Researcher</p></bio><bio xml:lang="ru"><p>д.м.н., ведущий научный сотрудник научного отдела</p></bio><email>kvsivak@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7656-4473</contrib-id><name-alternatives><name xml:lang="en"><surname>Perepelitsa</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Перепелица</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Urologist</p></bio><bio xml:lang="ru"><p>к.м.н., врач-уролог</p></bio><email>perepelitsa_vit@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6796-4064</contrib-id><name-alternatives><name xml:lang="en"><surname>Lelyavina</surname><given-names>T. A.</given-names></name><name xml:lang="ru"><surname>Лелявина</surname><given-names>Т. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher; PhD, MD, Leading Researcher</p></bio><bio xml:lang="ru"><p>научный сотрудник; д.м.н., ведущий научный сотрудник</p></bio><email>tatianalelyavina@mail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Malyshev</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Малышев</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher</p></bio><bio xml:lang="ru"><p>исследователь</p></bio><email>info@lucaclinic.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Saint Luka City Hospital</institution></aff><aff><institution xml:lang="ru">СПб ГБУЗ «Клиническая больница Святителя Луки»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">S.M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБВОУ ВО «Военно-медицинская академия им. С. М. Кирова»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Saint Petersburg State University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный университет</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">A.A. Smorodintsev Research Institute of Influenza of the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «НИИ гриппа им. А. А. Смородинцева» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">National Medical Research Center named after V.A. Almazov of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ НМИЦ им. В. А. Алмазова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-09-21" publication-format="electronic"><day>21</day><month>09</month><year>2024</year></pub-date><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>81</fpage><lpage>86</lpage><history><date date-type="received" iso-8601-date="2024-09-20"><day>20</day><month>09</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-09-20"><day>20</day><month>09</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО «Бионика Медиа»</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/1728-2985/article/view/636298">https://journals.eco-vector.com/1728-2985/article/view/636298</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> To compare thulium and holmium lasers in the treatment of non-muscle invasive bladder cancer (NMIBC).</p> <p><bold>Materials and methods.</bold> In our work, patients were divided into 3 groups, depending on the treatment method. In the group 1 (n=27, 32.14% of the cohort), thulium laser resection of the bladder was done, while in the group 2 (n=25, 29.76% of the cohort) and group 3 (n=32, 38.10 % of the cohort) holmium laser resection and standard transurethral resection (TUR) were performed, respectively. In the preoperative period, all patients underwent a standard clinical examinations and imaging studies (computed tomography of the thorax, abdomen and retroperitoneal space, magnetic resonance imaging of the pelvis, cystoscopy, cytological examination of urine sediment).</p> <p><bold>Results.</bold> The duration of the procedure was 14.7±5.2 minutes for a thulium laser and 16.3±5.3 minutes for a holmium laser, compared to 20.5±7.4 minutes for standard TUR. The duration of postoperative irrigation after laser resection was lower (4.4±1.8, 4.7±1.6 and 16.4±2.5 hours, respectively) (p&lt;0.001). The period of postoperative catheterization in groups 1 and 2 was 1.5±0.08 and 1.6±0.08 days, respectively, compared to 2.5± 0.13 days in the group 3 (p=0.002). In the group of thulium and holmium laser resection, a higher disease-free survival was demonstrated compared with TUR throughout the entire follow-up period.</p> <p><bold>Conclusion.</bold> When performing laser resection of the bladder wall for NMIBC, a significant lower number of complications and better survival were documented compared to patients who underwent TUR.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель работы:</bold> сравнение тулиевого и гольмиевого лазера при лечении немышечно-инвазивного рака мочевого пузыря (НМИРМП).</p> <p><bold>Материалы и методы.</bold> В ретроспективное исследование включены 84 пациента (средний возраст – 63,47±3,17 года) с первично выявленным образованием МП. В зависимости от метода лечения пациенты были разделены на три группы. Пациентам 1-й группы (n=27) была выполнена лазерная тулиевая резекция мочевого пузыря, 2-й группы (n=25) – лазерная гольмиевая резекция, 3-й группы (n=32) – стандартная трансуретральная резекция (ТУР). Всем пациентам в дооперационном периоде выполняли стандартный комплекс общеклинических и инструментальных методов исследования, в послеоперационном периоде оценивали клиническое состояние больных, частоту нежелательных явлений, выживаемость.</p> <p><bold>Результаты.</bold> Использование лазерной технологии позволило уменьшить продолжительность операции, которая составила 14,7±5,2 и 16,3±5,3 мин в 1-й и 2-й группах против 20,5±7,4 мин в группе ТУР. Также отмечено уменьшение длительности послеоперационного орошения в группах пациентов лазерной резекции: 4,4±1,8 ч в 1-й группе, 4,7±1,6 ч во 2-й и 16,4±2,5 ч – в 3-й группе (р&lt;0,001), сокращение сроков послеоперационной катетеризации до 1,5±0,08 и 1,6±0,08 дня в 1-й и 2-й группах по сравнению с 3-й группой (2,5±0,13 дня, р=0,002). В группе тулиевой и гольмиевой лазерной резекции при НМИРМП получены более высокие показатели безрецидивной выживаемости по сравнению с ТУР на протяжении всего периода наблюдения.</p> <p><bold>Выводы.</bold> При использовании лазерных технологий при резекции стенки мочевого пузыря по поводу НМИРМП зарегистрировано статистически значимо меньшее количество осложнений и лучшая выживаемость по сравнению с группой пациентов, перенесших ТУР.</p></trans-abstract><kwd-group xml:lang="en"><kwd>non-muscle invasive bladder cancer</kwd><kwd>transurethral resection of the bladder</kwd><kwd>laser resection</kwd><kwd>relapse</kwd><kwd>bladder</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>немышечно-инвазивный рак мочевого пузыря</kwd><kwd>трансуретральная резекция мочевого пузыря</kwd><kwd>лазерная резекция</kwd><kwd>рецидив</kwd><kwd>мочевой пузырь</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Gusniev M. A., Pechnikova V. V., Gushchin M. Yu., Gusniev S. A., Gioeva Z. V., Pshikhachev A.M., Mikhaleva L.M. Analysis of risk factors for recurrence of non-musculoskeletal invasive bladder cancer after its combined treatment. Medical Bulletin of the North Caucasus. 2022;17(3):264–268. Day https://doi.org/10.14300/mnnc.2022.17064. Russian (Гусниев М. А., Печникова В.В., Гущин М.Ю., Гусниев С.А., Гиоева З.В., Пшихачев А.М., Михалева Л.М. Анализ факторов риска рецидива немышечно-инвазивного рака мочевого пузыря после его комбинированного лечения. Медицинский вестник Северного Кавказа. 2022;17(3):264–268. Doi https://doi.org/10.14300/mnnc. 2022.17064).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Shore N.D., Palou Redorta J., Robert G., Hutson T.E., Cesari R., Hariharan S., Rodríguez Faba Ó., Briganti A., Steinberg G.D. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol. 2021;39(10):642–663. doi: 10.1016/j.urolonc.2021.05.015.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Al Hussein Al Awamlh, Chang, S.S. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Curr Oncol Rep. 2023;25:83–91. doi: 10.1007/s11912-022-01350-9.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ivakhno K.Yu., Vazhenin A.V., Karnaukh P.A., Misyukevich N.D. World experience in the use of a thule laser in the treatment of noninvasive muscle bladder cancer // Bulletin of the Council of Young Scientists of the Chelyabinsk region. 2018. № 1(20). URL: https://cyberleninka.ru/article/n/mirovoy-opyt-primenenie-tulievogo-lazera-v-lechenii-myshechno-neinvazivnogo-raka-mochevogo-puzyrya (date of application: 05/15/2023). Russian (Ивахно К.Ю., Важенин А.В., Карнаух П.А., Мисюкевич Н.Д. Мировой опыт применение тулиевого лазера в лечении мышечно-неинвазивного рака мочевого пузыря // Вестник Совета молодых ученых Челябинской области. 2018. № 1(20). URL: https://cyberleninka.ru/article/n/mirovoy-opyt-primenenie-tulievogo-lazera-v-lechenii-myshechno-neinvazivnogo-raka-mochevogo-puzyrya (дата обращения: 15.05.2023).</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Li C., Gao L., Zhang J., Yang X., Liu C. The effect of holmium laser resection versus standard transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Lasers Med Sci. 2020;35:1025–1034. 10.1007/s10103-020-02972-w</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Chen J., Zhao Y., Wang S., Jin X., Sun P., Zhang L., et al. Green-light laser en bloc resection for primary non-muscle-invasive bladder tumor vs. transurethral electroresection: a prospective, nonrandomized two-center trial with 36-month follow-up. Lasers Surg Med (2016;48:859–865. doi: 10.1002/lsm.22565</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Xu Y., Guan W., Chen W., Xie C., Ouyang Y., Wu Y., et al. Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: a prospective, randomized study. Lasers Surg Med. 2015;47:306–11. doi: 10.1002/lsm.22342</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Jin Y.H., Zeng X.T., Liu T.Z., Bai Z.M., Dou Z.L., Ding D.G., Fan Z.L., Han P., Huang Y.R., Huang X., Li M., Li X.D., Li Y.N., Li X.H., Liang C.Z., Liu J.M., Ma H.S., Qi J., Shi J.Q., Wang J., Wang D.L., Wang Z.P., Wang Y.Y., Wang Y.B,. Wei Q., Xia H.B., Xing J.C., Yan S.Y., Zhang X.P., Zheng G.Y., Xing N.Z., He D.L., Wang X.H.; Chinese Urological Doctor Association (CUDA), Urological Association of Chinese Research Hospital Association (CRHA-UA), Uro-Health Promotive Association of China International Exchange, Promotive Association for Medical, Health Care (CPAM-UHPA). Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9(1):44. doi: 10.1186/s40779-022-00406-y.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Musat M.G., Kwon C.S., Masters E., Sikirica S., Pijush D.B., Forsythe A. Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR). Clinicoecon Outcomes Res. 2022;14:35–48. https://doi.org/10.2147/CEOR.S341896</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Liem E. et al. Validation of Confocal Laser Endomicroscopy Features of Bladder Cancer: The Next Step Towards Real-time Histologic Grading. Eur Urol Focus. 2020;6:81. https://pubmed.ncbi.nlm.nih.gov/30033066.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Poletajew S., Krajewski W., Gajewska D., Sondka-Migdalska J., Borowik M., Buraczyński P., Dzięgała M., Łykowski M., Przudzik M., Tukiendorf A., Woźniak R., Bar K., Jabłonowski Z., Roslan M., Słojewski M., Zdrojowy R., Radziszewski P., Dziobek K. Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resection of bladder tumour – a prospective multicentre observational study. Arch Med Sci. 20197;16(4):863–870. doi: 10.5114/aoms.2019.88430.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kamadjou C., Kuitche J., Wadeu A., Mbassi A., Angwafo F. Transurethral Resection of Bladder Tumours: Results and Outcomes. Open Journal of Urology. 2022;12:342–356. doi: 10.4236/oju.2022.126033.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Lonati C., Esperto F., Scarpa R.M., Papalia R., Gómez Rivas J., Alvarez-Maestro M., Afferi L., Fankhauser C.D., Mattei A., Colombo R., Montorsi F., Briganti A., Krajewski W., Carando R., Laukhtina E., Teo J.Y., Zamboni S., Simeone C., Moschini M. European Association of Urology–Young Academic Urologists (EAU–YA U): Urothelial Carcinoma Working Group; European Association of Urology - European Society of Resident Urologists (EAU–ESRU). Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up. Minerva Urol Nephrol. 2022;74(5):570–580. doi: 10.23736/S2724-6051.21.04436-0.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kramer M.W. et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol 2015;33:1937. doi: 10.1007/s00345-015-1568-6.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hurle R. et al. “En Bloc” Resection of Nonmuscle Invasive Bladder Cancer: A Prospective Single-center Study. Urology 2016;90:126. doi: 10.1016/j.urology.2016.01.004.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Migliari R. et al. Thulium Laser Endoscopic En Bloc Enucleation of Non-muscleInvasive Bladder Cancer. J Endourol 2015;29:1258. doi: 10.1089/end.2015.0336.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Zhang X.R. et al. Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study. Photomed Laser Surg 2015;33:517. doi: 10.1089/pho.2015.3913.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Long G., Zhang Y., Sun G., Ouyang W., Liu Z., Li H. Safety and efficacy of thulium laser resection of bladder tumors versus transurethral resection of bladder tumors: a systematic review and meta-analysis. Lasers Med Sci. 2021;18:1–10. 10.1007/s10103-021-03272-7.</mixed-citation></ref></ref-list></back></article>
